Cardiac safety of liposomal anthracyclines

@article{Batist2007CardiacSO,
  title={Cardiac safety of liposomal anthracyclines},
  author={G. Batist},
  journal={Cardiovascular Toxicology},
  year={2007},
  volume={7},
  pages={72-74}
}
  • G. Batist
  • Published 2007
  • Medicine
  • Cardiovascular Toxicology
Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to… Expand
Anthracycline cardiotoxicity: from bench to bedside.
Cardiotoxicity of antitumor drugs.
Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice
The anthracyclines: When good things go bad
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).
Clinical Developments in Nanotechnology for Cancer Therapy
Targeted delivery of anti-cancer drugs by MS2 virus-like particles
...
1
2
3
4
...

References

SHOWING 1-10 OF 12 REFERENCES
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
  • S. Chia, M. Clemons, +4 authors L. Panasci
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Phase II trial of Taxol, Trastuzumab plus non-pegylated liposomal doxorubicin in locally advanced and metastatic breast cancer. ASCO
  • Cardiovasc Toxicol
  • 2005
...
1
2
...